TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Immatics ( (IMTX) ) has shared an announcement.
Immatics N.V. released its interim report for the three- and nine-month periods ending September 30, 2025, revealing significant financial results. The company reported a net loss of €50.5 million for the third quarter and €160.7 million for the nine months, with revenues from collaboration agreements reaching €5.2 million and €28.5 million, respectively. The report highlights ongoing challenges in research and development expenses, which amounted to €47.2 million for the quarter. This financial update underscores the company’s continued investment in its research pipeline and the inherent risks associated with its clinical trials and regulatory processes.
The most recent analyst rating on (IMTX) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Immatics stock, see the IMTX Stock Forecast page.
Spark’s Take on IMTX Stock
According to Spark, TipRanks’ AI Analyst, IMTX is a Neutral.
The overall stock score is primarily influenced by financial performance challenges, including declining revenues and cash flow issues. However, the stock’s technical indicators are strong, showing positive momentum. Valuation remains a concern due to negative earnings and lack of dividends.
To see Spark’s full report on IMTX stock, click here.
More about Immatics
Immatics N.V. operates in the biotechnology industry, focusing on the development of T-cell receptor-based immunotherapies for cancer treatment. The company leverages its proprietary technology platforms to discover and develop novel therapies aimed at targeting a range of cancer types.
Average Trading Volume: 870,194
Technical Sentiment Signal: Buy
Current Market Cap: $1.24B
See more data about IMTX stock on TipRanks’ Stock Analysis page.